Mohd Nafi Siti Norasikin, Idris Fauziah, Jaafar Hasnan
Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kota Bharu, Kelantan, Malaysia. Email:
Asian Pac J Cancer Prev. 2017 Dec 28;18(12):3231-3238. doi: 10.22034/APJCP.2017.18.12.3231.
Background: Angiogenic activity has been considered to reflect important molecular events during breast tumour development. The present study concerned cellular and molecular changes of MNU-induced breast tumours subjected to promotion and suppression of angiogenesis. Methods: Female Sprague Dawley rats at the age of 21 days received MNU at the dose 70 mg/kg of body weight by intraperitoneal injection. Three months post-carcinogen initiation, mammary tumours were palpated and their growth was monitored. When the tumour diameter reached 1.0 ± 0.05 cm, rats were given bFGF or PF4 intratumourally at a dose of 10 μg/tumour. Entire palpable tumour were subsequently excised and subjected to histology examination, IHC staining, and RT-PCR. Results: No critical morphological changes were observed between pro-angiogenic factor, bFGF, and control groups. However, increase of tumour size with more necrotic and diffuse areas was notable in tumours after anti-angiogenic PF4 intervention. ER and PR mRNA expression was significantly up- and down-regulated in bFGF and PF4 groups, respectively. The trends were significantly associated with peri- and intratumoural MVD counts. However, irrespective of whether we promoted or inhibited angiogenesis, the expression of EGFR and ERBB2 continued to be significantly increased but this was not significantly associated with the MVD score. No significant differences in E-cadherin and LR gene expression were noted between intervention and control groups. Conclusion: ER and PR receptor expression shows consistent responses when tumour angiogenesis is manipulated either positively or negatively. Our study adds to current understanding that not only do we need to target hormonal receptors, as presently practiced, but we also need to target endothelial receptors to successfully treat breast cancer.
血管生成活性被认为反映了乳腺肿瘤发生过程中的重要分子事件。本研究关注了经血管生成促进和抑制处理的N-甲基-N-亚硝基脲(MNU)诱导的乳腺肿瘤的细胞和分子变化。
21日龄的雌性斯普拉格-道利大鼠通过腹腔注射给予70mg/kg体重剂量的MNU。致癌剂诱发三个月后,触诊乳腺肿瘤并监测其生长。当肿瘤直径达到1.0±0.05cm时,以10μg/肿瘤的剂量将碱性成纤维细胞生长因子(bFGF)或血小板因子4(PF4)瘤内注射给大鼠。随后切除整个可触及的肿瘤并进行组织学检查、免疫组化染色和逆转录-聚合酶链反应(RT-PCR)。
促血管生成因子bFGF组与对照组之间未观察到关键的形态学变化。然而,抗血管生成的PF4干预后,肿瘤大小增加,坏死和弥漫区域增多。bFGF组和PF4组中雌激素受体(ER)和孕激素受体(PR)的mRNA表达分别显著上调和下调。这些趋势与肿瘤周围和瘤内微血管密度(MVD)计数显著相关。然而,无论我们促进还是抑制血管生成,表皮生长因子受体(EGFR)和人表皮生长因子受体2(ERBB2)的表达持续显著增加,但这与MVD评分无显著相关性。干预组和对照组之间E-钙黏蛋白和LR基因表达无显著差异。
当肿瘤血管生成被正向或负向调控时,ER和PR受体表达呈现一致的反应。我们的研究进一步加深了目前的认识,即我们不仅需要像目前实践中那样靶向激素受体,还需要靶向内皮受体来成功治疗乳腺癌。